- Home
- CIK vs FATE Comparison
CIK vs FATE Comparison
Compare CIK & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- FATE
- Stock Information
- Founded
- CIK 1987
- FATE 2007
- Country
- CIK United States
- FATE United States
- Employees
- CIK N/A
- FATE N/A
- Industry
- CIK Finance/Investors Services
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIK Finance
- FATE Health Care
- Exchange
- CIK Nasdaq
- FATE Nasdaq
- Market Cap
- CIK 159.3M
- FATE 142.4M
- IPO Year
- CIK N/A
- FATE 2013
- Fundamental
- Price
- CIK $2.95
- FATE $1.42
- Analyst Decision
- CIK
- FATE Hold
- Analyst Count
- CIK 0
- FATE 10
- Target Price
- CIK N/A
- FATE $6.75
- AVG Volume (30 Days)
- CIK 115.4K
- FATE 2.1M
- Earning Date
- CIK 01-01-0001
- FATE 03-04-2025
- Dividend Yield
- CIK 9.03%
- FATE N/A
- EPS Growth
- CIK N/A
- FATE N/A
- EPS
- CIK N/A
- FATE N/A
- Revenue
- CIK N/A
- FATE $13,447,000.00
- Revenue This Year
- CIK N/A
- FATE N/A
- Revenue Next Year
- CIK N/A
- FATE N/A
- P/E Ratio
- CIK N/A
- FATE N/A
- Revenue Growth
- CIK N/A
- FATE N/A
- 52 Week Low
- CIK $2.50
- FATE $1.04
- 52 Week High
- CIK $3.19
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- CIK 50.60
- FATE 48.76
- Support Level
- CIK $2.92
- FATE $1.43
- Resistance Level
- CIK $2.98
- FATE $1.81
- Average True Range (ATR)
- CIK 0.03
- FATE 0.14
- MACD
- CIK -0.00
- FATE 0.05
- Stochastic Oscillator
- CIK 33.33
- FATE 39.06
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.